Forest Laboratories has inked a deal to buy the North American rights to Pierre Fabre Medicament's experimental anti-depressant F2695 for $75 million. An undisclosed set of milestone payments are also ...
> Forest Laboratories and Gedeon Richter announced preliminary top-line results from a mid-stage clinical trial of the antipsychotic cariprazine showing that patients with acute manic episodes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results